As of March 22, 2022, an updated single statewide medication assisted treatment (MAT) formulary is in effect. In accordance with Social Services Law Title 11, Section 364-j (26) (b), managed care providers shall not require prior authorization for any buprenorphine products, methadone or long-acting injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.
Single statewide MAT formulary effective March 22, 2022
Please take note of the updated MAT formulary as outlined below.
|naloxone (syringe, vial)
Narcan® (nasal spray)
naloxone nasal spray
|Opioid Dependence Agents - Injectable*|
|Opioid Dependence Agents- Oral / Transmucosal*|
*All agents subject to FDA approved quantity /frequency /duration limits. **Added per NYS Nov. 2021 DURB recommendation.
Download the latest MAT formulary to share this news with your peers.
Prior authorization guidance
For opioid antagonists and opioid dependence agents:
Review the latest New York Medicaid Update article for additional information from NYSDOH. Consult the UHCNY preferred drug list for prescription guidance.
For answers to specific questions, please email firstname.lastname@example.org.